Literature DB >> 25417238

Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer.

Margaret R Stedman1, Eric J Feuer2, Angela B Mariotto2.   

Abstract

BACKGROUND: The probability of cure is a long-term prognostic measure of cancer survival. Estimates of the cure fraction, the proportion of patients "cured" of the disease, are based on extrapolating survival models beyond the range of data. The objective of this work is to evaluate the sensitivity of cure fraction estimates to model choice and study design.
METHODS: Data were obtained from the Surveillance, Epidemiology, and End Results (SEER)-9 registries to construct a cohort of breast and colorectal cancer patients diagnosed from 1975 to 1985. In a sensitivity analysis, cure fraction estimates are compared from different study designs with short- and long-term follow-up. Methods tested include: cause-specific and relative survival, parametric mixture, and flexible models. In a separate analysis, estimates are projected for 2008 diagnoses using study designs including the full cohort (1975-2008 diagnoses) and restricted to recent diagnoses (1998-2008) with follow-up to 2009.
RESULTS: We show that flexible models often provide higher estimates of the cure fraction compared to parametric mixture models. Log normal models generate lower estimates than Weibull parametric models. In general, 12 years is enough follow-up time to estimate the cure fraction for regional and distant stage colorectal cancer but not for breast cancer. 2008 colorectal cure projections show a 15% increase in the cure fraction since 1985. DISCUSSION: Estimates of the cure fraction are model and study design dependent. It is best to compare results from multiple models and examine model fit to determine the reliability of the estimate. Early-stage cancers are sensitive to survival type and follow-up time because of their longer survival. More flexible models are susceptible to slight fluctuations in the shape of the survival curve which can influence the stability of the estimate; however, stability may be improved by lengthening follow-up and restricting the cohort to reduce heterogeneity in the data. Published by Oxford University Press 2014.

Entities:  

Mesh:

Year:  2014        PMID: 25417238      PMCID: PMC5964975          DOI: 10.1093/jncimonographs/lgu015

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  16 in total

1.  Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

2.  Cure fraction estimation from the mixture cure models for grouped survival data.

Authors:  Binbing Yu; Ram C Tiwari; Kathleen A Cronin; Eric J Feuer
Journal:  Stat Med       Date:  2004-06-15       Impact factor: 2.373

3.  Estimating and modeling the cure fraction in population-based cancer survival analysis.

Authors:  Paul C Lambert; John R Thompson; Claire L Weston; Paul W Dickman
Journal:  Biostatistics       Date:  2006-10-04       Impact factor: 5.899

4.  CANSURV: A Windows program for population-based cancer survival analysis.

Authors:  Binbing Yu; Ram C Tiwari; Kathleen A Cronin; Chris McDonald; Eric J Feuer
Journal:  Comput Methods Programs Biomed       Date:  2005-10-27       Impact factor: 5.428

5.  Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?

Authors:  Lan Huang; Kathleen A Cronin; Karen A Johnson; Angela B Mariotto; Eric J Feuer
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

6.  Trends in 'cure' fraction from colorectal cancer by age and tumour stage between 1975 and 2000, using population-based data, Osaka, Japan.

Authors:  Yuri Ito; Tomio Nakayama; Isao Miyashiro; Tomoyuki Sugimoto; Akiko Ioka; Hideaki Tsukuma; Manar E Abdel-Rahman; Bernard Rachet
Journal:  Jpn J Clin Oncol       Date:  2012-09-05       Impact factor: 3.019

7.  'Cure' from breast cancer among two populations of women followed for 23 years after diagnosis.

Authors:  L M Woods; B Rachet; P C Lambert; M P Coleman
Journal:  Ann Oncol       Date:  2009-05-22       Impact factor: 32.976

8.  Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models.

Authors:  Therese M L Andersson; Paul W Dickman; Sandra Eloranta; Paul C Lambert
Journal:  BMC Med Res Methodol       Date:  2011-06-22       Impact factor: 4.615

9.  Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database.

Authors:  Patricia Tai; Edward Yu; Gábor Cserni; Georges Vlastos; Melanie Royce; Ian Kunkler; Vincent Vinh-Hung
Journal:  BMC Cancer       Date:  2005-05-17       Impact factor: 4.430

10.  Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry.

Authors:  Paul C Lambert; Paul W Dickman; Pia Österlund; Therese Andersson; Risto Sankila; Bengt Glimelius
Journal:  Int J Cancer       Date:  2007-11-01       Impact factor: 7.396

View more
  2 in total

1.  Cancer survival: an overview of measures, uses, and interpretation.

Authors:  Angela B Mariotto; Anne-Michelle Noone; Nadia Howlader; Hyunsoon Cho; Gretchen E Keel; Jessica Garshell; Steven Woloshin; Lisa M Schwartz
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

2.  Prognosis and cure of long-term cancer survivors: A population-based estimation.

Authors:  Luigino Dal Maso; Chiara Panato; Stefano Guzzinati; Diego Serraino; Silvia Francisci; Laura Botta; Riccardo Capocaccia; Andrea Tavilla; Anna Gigli; Emanuele Crocetti; Massimo Rugge; Giovanna Tagliabue; Rosa Angela Filiberti; Giuliano Carrozzi; Maria Michiara; Stefano Ferretti; Rosaria Cesaraccio; Rosario Tumino; Fabio Falcini; Fabrizio Stracci; Antonietta Torrisi; Guido Mazzoleni; Mario Fusco; Stefano Rosso; Francesco Tisano; Anna Clara Fanetti; Giovanna Maria Sini; Carlotta Buzzoni; Roberta De Angelis
Journal:  Cancer Med       Date:  2019-06-17       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.